The company wanted to access the safety and tolerability of the drug, NXY-059, in intracerebral hemorrhage (ICH) as treatment may be initiated before a scan has confirmed diagnosis of acute ischemic stroke (AIS).
The data showed that the safety and tolerability of NXY-059 in ICH patients was similar to placebo, with comparable mortality rates of 20% in each group.
“Our evolving understanding of the safety and tolerability profile of NXY-059 in acute stroke conditions is enhanced greatly by the CHANT trial results,” commented Dr Tomas Odergren, global product director for NXY-059 at AstraZeneca.
NXY-059 is currently being studied as a neuroprotectant in phase III clinical trials for the treatment of acute ischemic stroke by AstraZeneca. The compound was licensed from US biopharmaceutical company, Renovis, Inc.